WALVAX BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.32 CNY | -0.08% |
|
-7.78% | -47.60% |
| Sales 2024 * | 4.13B 570M | Sales 2025 * | 5.36B 740M | Capitalization | 19.68B 2.72B |
|---|---|---|---|---|---|
| Net income 2024 * | 781M 108M | Net income 2025 * | 1.12B 155M | EV / Sales 2024 * | 3.75 x |
| Net cash position 2024 * | 4.17B 575M | Net cash position 2025 * | 4.77B 658M | EV / Sales 2025 * | 2.78 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
17.7
x | Employees | 2,388 |
| Yield 2024 * |
0.81% | Yield 2025 * |
0.97% | Free-Float | 85.34% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -0.08% | ||
| 1 week | -7.78% | ||
| Current month | -7.78% | ||
| 1 month | -18.36% | ||
| 3 months | -28.70% | ||
| 6 months | -45.75% | ||
| Current year | -47.60% |
1 week
12.25
13.25
1 month
12.2515.59
Current year
12.2523.66
1 year
12.2528.45
3 years
12.2596.73
5 years
12.2596.73
10 years
5.0596.73
| Managers | Title | Age | Since |
|---|---|---|---|
Run Sheng Jiang
PSD | President | 67 | 16-06-21 |
Hua Zhou
DFI | Director of Finance/CFO | 57 | 14-06-22 |
Shao zhong Dong
BRD | Director/Board Member | 56 | 22-01-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ling Bing Zeng
BRD | Director/Board Member | 67 | 22-10-12 |
Zhen Huang
BRD | Director/Board Member | 61 | 02-12-31 |
Yun Chun Li
CHM | Chairman | 62 | 09-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 12.32 | -0.08% | 12,417,050 |
| 24-06-06 | 12.33 | -4.42% | 20,029,300 |
| 24-06-05 | 12.9 | +0.08% | 13,946,070 |
| 24-06-04 | 12.89 | -0.15% | 14,828,270 |
| 24-06-03 | 12.91 | -3.37% | 20,975,690 |
End-of-day quote Shenzhen S.E., June 06, 2024
More quotes
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
12.32
CNY
Average target price
20
CNY
Spread / Average Target
+62.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.60% | 2.72B | |
| +0.82% | 91.94B | |
| -1.32% | 38.74B | |
| -12.88% | 32.82B | |
| +64.77% | 26.66B | |
| -16.31% | 15.32B | |
| -5.78% | 13.3B | |
| -11.38% | 11.65B | |
| -49.84% | 10.12B | |
| +5.24% | 9.06B |
- Stock Market
- Equities
- 300142 Stock
